Novo Nordisk, CagriSema, Obesity Treatment, Weight Management, Semaglutide, Cagrilintide, REDEFINE 1, Phase 3 Clinical Trial, Menopause Research, GLP-1 Receptor Agonist

Plainsboro, New Jersey, United States, and Bagsværd, Denmark, October 20, 2026 Novo Nordisk has announced promising findings from two...